RxDoctor Payments DataLook up a doctor →

Kristofer Charlton-Ouw, MD

Vascular Surgery · Houston, TXNPI 1104995828

Payments from drug & device makers

$240,320in general payments, 2019–2025

Across 396 payments — averaging $606.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$62K
  • Bard Peripheral Vascular, Inc.$49K
  • Abbott$43K
  • W. L. Gore & Associates, Inc.$36K
  • Janssen Research & Development, LLC$28K
  • Merit Medical Systems Inc$11K
  • plus $11K from 45 others

What the payments were for

  • Consulting fees$15,14642%
  • Speaking & faculty fees$3501%
  • Travel & lodging$4,42812%
  • Food & beverage$15,83644%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$240,320 in reported general payments places this provider in the 95th percentile of 347 vascular surgery providers in Texas.

See all vascular surgery providers in Texas

Medicare billing

Part B allowed, 2024
$200,983
Medicare patients
209
Services billed
1,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban22$22,521
EliquisApixaban20$13,370
Cilostazol69$1,340
ClopidogrelClopidogrel Bisulfate80$699
Gabapentin55$429
Atorvastatin Calcium31$202
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$76
Tramadol Hcl32$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$659$22,52122 claims
PfizerEliquis$50$13,37020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 vascular surgery providers in Texas.

Other vascular surgery in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →